Across the recent three months, 7 analysts have shared their insights on Oscar Health (NYSE:OSCR), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 1 | 2 | 3 | 1 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 0 | 1 | 1 | 1 |
| 2M Ago | 0 | 0 | 0 | 2 | 0 |
| 3M Ago | 0 | 1 | 0 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $13.43, a high estimate of $18.00, and a low estimate of $10.00. This current average has decreased by 29.94% from the previous average price target of $19.17.
Deciphering Analyst Ratings: An In-Depth Analysis
An in-depth analysis of recent analyst actions unveils how financial experts perceive Oscar Health. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Jessica Tassan | Piper Sandler | Lowers | Neutral | $13.00 | $14.00 |
| Michael Ha | Baird | Lowers | Neutral | $14.00 | $28.00 |
| Andrew Mok | Barclays | Lowers | Underweight | $11.00 | $17.00 |
| Jonathan Yong | UBS | Lowers | Sell | $11.00 | $15.00 |
| Stephen Baxter | Wells Fargo | Lowers | Underweight | $10.00 | $16.00 |
| Andrew Mok | Barclays | Announces | Underweight | $17.00 | - |
| Jessica Tassan | Piper Sandler | Lowers | Overweight | $18.00 | $25.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Oscar Health. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Oscar Health compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Oscar Health's stock. This comparison reveals trends in analysts' expectations over time.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Oscar Health's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Oscar Health analyst ratings.
Unveiling the Story Behind Oscar Health
Oscar Health Inc is a health insurance company. The company provides various insurance plans for individuals, families, and employees. Also, the company provides virtual care, doctor support, scheduling appointments, and other related services. The company provides plans in the Medicare Advantage program to adults who are age 65 and older and eligible for traditional Medicare but who instead select coverage through a private market plan.
Oscar Health's Economic Impact: An Analysis
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Oscar Health's remarkable performance in 3M is evident. As of 30 June, 2025, the company achieved an impressive revenue growth rate of 29.04%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Financials sector.
Net Margin: Oscar Health's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -7.97%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Oscar Health's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -18.33%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Oscar Health's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -3.74%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Oscar Health's debt-to-equity ratio is below the industry average at 0.26, reflecting a lower dependency on debt financing and a more conservative financial approach.
The Significance of Analyst Ratings Explained
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
